Cancer Research and Treatment

Original Articles

Pilot Study for Feasibility of Onco-Geriatric Intervention Model in Older Patients with Cancer in a Tertiary Academic Hospital: Jin Won Kim, Jung-Yeon Choi, Woochan Park, Minsu Kang, Jeongmin Seo, Eun Hee Jung, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Sang-A Kim, Ji Yun Lee, Jeong-Ok Lee, Soo-Mee Bang, Kwang-il Kim, Jee Hyun Kim; Received January 20, 2025 Accepted March 11, 2025 Published online March 12, 2025; DOI: https://doi.org/10.4143/crt.2025.079 [Accepted]

Abstract PDF: Purpose
Older cancer patients face unique challenges due to age-related physiological changes, increasing their vulnerability to treatment-related toxicities. Geriatric assessment (GA) is a validated tool for optimizing care, yet there is no consensus on integrating geriatric interventions into oncology. This study evaluates the feasibility of a tailored onco-geriatric intervention model incorporating the KG-7 screening tool.
Materials and Methods
This prospective study included 30 patients aged ≥70 years with solid tumors undergoing adjuvant or palliative chemotherapy. Patients scoring ≤5 of KG-7 were eligible. Tailored interventions incorporating KG-7 included polypharmacy, functional status, mobility, nutrition, cognition, emotional well-being, insomnia, social support, and medical problem. KG-7, GA, and quality of life (QoL) were followed at 12 weeks.
Results
Participants (median age: 79.5 years) had colon (43.3%), pancreatic (23.3%), or gastric cancer (23.3%). At baseline, most patients showed independent ADL (100%)/IALD (90%). However, 93.3% had abnormal GA. Particularly, 86.7% were either malnourished or at risk of malnutrition. The most frequently identified intervention needs included polypharmacy (70.0%), nutritional support (60.0%), and emotional well-being (50.0%) with high adherence (100.0%, 88.9%, and 46.7%, respectively). At 12 weeks, KG-7 scores improved in 43.8% of patients, and 69.2% of GA domains were improved. QoL analysis revealed modest improvement in Global Health Status (mean difference 6.3, p=0.176). One-year survival rates were 92.3% and 79.4% for adjuvant and palliative groups, respectively.
Conclusion
The onco-geriatric intervention model incorporating KG-7 demonstrated high feasibility and potential to enhance clinical outcomes. Future studies should validate this approach in randomized trials to optimize care for older cancer patients.

378 View
11 Download

Validating the Korean Geriatric Assessment Tool in Elderly Multiple Myeloma Patients: A Multicenter Study: Ji Yun Lee, Sang-A Kim, Youngil Koh, Ho-Young Yhim, Gyeong-Won Lee, Chang-Ki Min, Young Rok Do, Hyo Jung Kim, Sung Hwa Bae, Hyeon-Seok Eom, Sung-Hoon Jung, Hyunkyung Park, Seung-Hyun Nam, Ji Hyun Lee, Sung-Hyun Kim, Hyun Jung Lee, Young Seob Park, Soo-Mee Bang; Received January 15, 2025 Accepted February 20, 2025 Published online February 21, 2025; DOI: https://doi.org/10.4143/crt.2025.066 [Accepted]

Abstract PDF: Purpose
This study evaluates the Korean Cancer Study Group Geriatric Score-7 (KG-7) frailty screening tool's effectiveness in elderly multiple myeloma (MM) patients to prevent under and over-treatment.
Materials and Methods
This prospective pilot cohort study included 100 elderly patients aged 70 and older with newly diagnosed MM who had not undergone transplantation from August 2020 to January 2022.
Results
The median age was 77 years, and 73% of patients were classified at International Staging System (ISS) stages 2 or 3. Using a 5-point cutoff on the KG-7 index (non-frail, score ≥ 5; frail, score < 5), 31% were categorized as frail. After a median follow-up of 26.8 months, the 3-year overall survival rate was 73.0%. There was no statistically significant association between any frailty index and the risk of death. However, frail patients defined by the simplified frailty index (HR, 2.49; 95% CI, 1.09–5.95; p=0.030) and by KG-7 (HR, 2.43; 95% CI, 1.03–5.86; p=0.043) had a significantly higher risk of grade 3–4 non-hematologic toxicity, whereas the IMWG definition did not. Over a 24-month tracking period, vulnerability as measured by KG-7 either improved or deteriorated.
Conclusion
The pilot study, which had a limited number of participants, did not demonstrate KG-7’s effectiveness in predicting survival; however, it successfully predicted severe non-hematologic toxicities. We plan to conduct larger studies in elderly MM patients to determine whether KG-7 can help tailor their treatment regimens.

469 View
14 Download

Hematologic malignancy

The Role of Direct Oral Anticoagulants in Managing Myeloproliferative Neoplasms Patients: Ji Yun Lee, Ju-Hyun Lee, Woochan Park, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang; Cancer Res Treat. 2025;57(2):612-620. Published online September 20, 2024; DOI: https://doi.org/10.4143/crt.2024.738

Abstract PDF Supplementary Material PubReader ePub

Purpose
Thrombosis and bleeding significantly affect morbidity and mortality in myeloproliferative neoplasms (MPNs). The efficacy and safety of direct oral anticoagulants (DOACs) in MPN patients remain uncertain.
Materials and Methods
We conducted a large, retrospective, nationwide cohort study using the Korean Health Insurance Review and Assessment Service database from 2010 to 2021.
Results
Out of the 368 MPN patients included in the final analysis, 62.8% were treated with DOACs for atrial fibrillation (AF), and 37.2% for venous thromboembolism (VTE). The AF group was statistically older with higher CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism, vascular disease, age 65-74 years, sex category [female]) scores compared to the VTE group. Antiplatelet agents were used in 51.1% of cases, and cytoreductive drugs in 79.3%, with hydroxyurea being the most common (64.9%). The median follow-up was 22.3 months, with 1-year cumulative incidence rates of thrombosis and bleeding at 11.1% and 3.7%, respectively. Multivariate analysis identified CHA2DS2-VASc scores ≥ 3 (hazard ratio [HR], 3.48), concomitant antiplatelet use (HR, 2.57), and cytoreduction (HR, 2.20) as significant thrombosis risk factors but found no significant predictors for major bleeding.
Conclusion
Despite the limitations of retrospective data, DOAC treatment in MPN patients seems effective and has an acceptable bleeding risk.

Citations

Citations to this article as recorded by

Survey of Clinical Practice in Chronic Myeloproliferative Neoplasms in Croatia: A Study by the MPN Working Group Party of the Croatian Cooperative Group for Hematologic Diseases (KROHEM)
Ivan Krecak, Marko Lucijanic, Rajko Kusec
Journal of Clinical Medicine.2025; 14(5): 1524. CrossRef

980 View
91 Download
1 Crossref

Lung and Thoracic cancer

Association of TP53 Mutation Status and Sex with Clinical Outcome in Non–Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Retrospective Cohort Study: Songji Choi, Se Hyun Kim, Sejoon Lee, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji Yun Lee, Ji-Won Kim, Jin Won Kim, Jeong-Ok Lee, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee; Cancer Res Treat. 2025;57(1):70-82. Published online August 7, 2024; DOI: https://doi.org/10.4143/crt.2024.046

Abstract PDF Supplementary Material PubReader ePub

Purpose
Some studies suggest that TP53 mutations are associated with the response to immune checkpoint inhibitors (ICI) in patients with non–small cell lung cancer (NSCLC) and also contribute to sex disparities in several cancers. Thus, we hypothesized that TP53 mutations might serve as sex-dependent genomic biomarkers of ICI treatment response in patients with NSCLC.
Materials and Methods
Clinical data of 100 patients with metastatic NSCLC treated with ICI monotherapy at Seoul National University Bundang Hospital (SNUBH) were retrospectively reviewed. Genomic and clinical datasets of The Cancer Genome Atlas and an ICI-treated lung cancer cohort (cBioPortal) were also analyzed.
Results
In SNUBH cohort, no statistically significant difference was observed in the median progression-free survival (PFS) according to TP53 mutation status (p=0.930); however, female patients with TP53 mutations (MT) had a significantly prolonged median PFS compared to wild-type (WT) (6.1 months in TP53 MT vs. 2.6 months in TP53 WT; p=0.021). Programmed death-ligand 1 (PD-L1) high (≥ 50%) expression was significantly enriched in female patients with TP53 MT (p=0.005). The analysis from publicly available dataset also revealed that females with NSCLC with TP53 MT showed significantly longer PFS than those with TP53 WT (p < 0.001). In The Cancer Genome Atlas analysis, expression of immune-related genes, and tumor mutation burden score in TP53 MT females were higher than in males without TP53 MT.
Conclusion
Female patients with NSCLC with TP53 mutations had high PD-L1 expression and showed favorable clinical outcomes following ICI therapy, suggesting a need for further research to explore the role of TP53 mutations for sex disparities in response to ICI therapy.

Citations

Citations to this article as recorded by

Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics
Clelia Madeddu, Eleonora Lai, Manuela Neri, Elisabetta Sanna, Giulia Gramignano, Sonia Nemolato, Mario Scartozzi, Sabrina Giglio, Antonio Macciò
International Journal of Molecular Sciences.2025; 26(5): 2232. CrossRef

1,523 View
156 Download
1 Web of Science
1 Crossref

Hematologic malignancy

Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea: Ji Yun Lee, Ji Hyun Kwon, Joon Young Hur, Jun Ho Yi, Ji Hyun Lee, Hyungwoo Cho, Young Rok Do, Jae-Cheol Jo, Hye Jin Kang, Yougil Koh, Won Sik Lee, Sung Nam Lim, Sang Eun Yoon, Seok Jin Kim, Jeong-Ok Lee; Cancer Res Treat. 2024;56(2):681-687. Published online November 10, 2023; DOI: https://doi.org/10.4143/crt.2023.1042

Abstract PDF PubReader ePub

Purpose
Programmed death-1 blockade with pembrolizumab has shown promising activity in relapsed/refractory (R/R) extranodal natural killer/T-cell lymphoma (NKTCL), but studies are limited, with small patient numbers.
Materials and Methods
Thirteen institutes involved with the Consortium for Improving Survival of Lymphoma, a Korean lymphoma study group, collected the clinical data of 59 patients treated with pembrolizumab as salvage therapy between 2016 and 2022.
Results
The median age of the patients was 60 years (range, 22 to 87 years), and 76.3% had advanced Ann Abor stage disease. Pembrolizumab was given to 35.6%, 40.7%, and 23.7% of the patients as second-, third-, and fourth- or higher-line chemotherapy, respectively. The overall response rate was 40.7%, with 28.8% having complete response. The estimated 2-year progression-free survival (PFS) and overall survival rates for all patients were 21.5% and 28.7%, respectively; for responders, the rates were 53.0% and 60.7%, respectively. Although not statistically significant, Eastern Cooperative Oncology Group performance status ≥ 2 (hazard ratio [HR], 1.91; 95% confidence interval [95% CI], 0.93 to 3.94; p=0.078) and stage III or IV disease (HR, 2.59; 95% CI, 0.96 to 6.96; p=0.060) were associated with a trend toward shorter PFS in multivariate analysis. Grade 3 or 4 adverse events (AEs) were noted in 12 patients (20.3%); neutropenia (10.2%), fatigue (6.8%), and pneumonitis (5.1%) were most common AEs.
Conclusion
In conclusion, while pembrolizumab had a modest effect on patients with R/R NKTCL, it may be a useful salvage therapy for patients with localized disease and good performance status.

Citations

Citations to this article as recorded by

An evaluation of sugemalimab for the treatment of relapsed or refractory extranodal natural killer T-cell lymphoma
Yingfang Feng, Xia Liu, Jingwei Yu, Zheng Song, Lanfang Li, Lihua Qiu, Shiyong Zhou, Zhengzi Qian, Xianhuo Wang, Huilai Zhang
Expert Opinion on Biological Therapy.2025; 25(1): 9. CrossRef
Pembrolizumab

Reactions Weekly.2024; 2025(1): 390. CrossRef

3,886 View
214 Download
1 Web of Science
2 Crossref

Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer: Junghoon Shin, Jin-Haeng Chung, Se Hyun Kim, Kyu Sang Lee, Koung Jin Suh, Ji Yun Lee, Ji-Won Kim, Jeong-Ok Lee, Jin-Won Kim, Yu-Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong-Seok Lee; Cancer Res Treat. 2019;51(3):1086-1097. Published online November 5, 2018; DOI: https://doi.org/10.4143/crt.2018.537

Abstract PDF PubReader ePub

Purpose
Programmed death-1 (PD-1)/PD-1 ligand (PD-L1) axis blockades have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). We assessed the effect of platinum-based chemotherapy on tumor PD-L1 expression and its clinical implications.
Materials and Methods
We used immunohistochemistry to retrospectively evaluate the percentage of tumor cells with membranous PD-L1 staining (tumor proportion score) in paired tumor specimens obtained before and after platinum-based neoadjuvant chemotherapy (NACT) in 86 patients with NSCLC. We analyzed the correlation between the change in PD-L1 tumor proportion score and clinicopathologic characteristics, response to NACT, and survival.
Results
The PD-L1 tumor proportion score increased in a significant proportion of patients with NSCLC after platinum-based NACT (Wilcoxon signed-rank test, p=0.002). That pattern was consistent across clinically defined subgroups except for patients with partial response to NACT. Tumors from 26 patients (30.2%) were PD-L1‒negative before NACT but PD-L1-positive after NACT, whereas the reverse pattern occurred in six patients (7%) (McNemar’s test, p < 0.001). Increase in PD-L1 tumor proportion score was significantly associated with lack of response to NACT (Fisher exact test, p=0.015). There was a tendency, albeit not statistically significant, for patients with an increase in PD-L1 tumor proportion score to have shorter survival.
Conclusion
Tumor PD-L1 expression increased after platinum-based NACT in a significant proportion of patients with NSCLC. Increase in tumor PD-L1 expression may predict poor clinical outcome.

Citations

Citations to this article as recorded by

Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project
Martina Haberecker, Jan H. Rüschoff, Charitini Andriakopoulou, Steven G. Gray, Kristiaan Nackaerts, Marc De Perrot, Luka Brcic, Ernest Nadal, Sotirios Tsimpoukis, Luca Ampollini, Joachim G. Aerts, Michaela B. Kirschner, Kim Monkhorst, Birgit Weynand, Fate
JCO Precision Oncology.2025;[Epub] CrossRef
Selenium-containing compounds, selenium nanoparticles and selenoproteins in the prevention and treatment of lung cancer
Elena G. Varlamova
Journal of Trace Elements in Medicine and Biology.2025; 88: 127620. CrossRef
Potential Predictive Immune and Metabolic Biomarkers of Tumor Microenvironment Regarding Pathological and Clinical Response in Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Systematic Review
H. H. Wang, E. N. Steffens, G. Kats-Ugurlu, B. van Etten, J. G. M. Burgerhof, G. A. P. Hospers, J. T. M. Plukker
Annals of Surgical Oncology.2024; 31(1): 433. CrossRef
Redetermination of PD-L1 expression after chemio-radiation in locally advanced PDL1 negative NSCLC patients: retrospective multicentric analysis
Patrizia Ciammella, Salvatore Cozzi, Paolo Borghetti, Marco Galaverni, Valerio Nardone, Maria Paola Ruggieri, Matteo Sepulcri, Vieri Scotti, Alessio Bruni, Francesca Zanelli, Roberto Piro, Elena Tagliavini, Andrea Botti, Federico Iori, Emanuele Alì, Chiar
Frontiers in Oncology.2024;[Epub] CrossRef
First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET
Johanna E E Pouw, Sayed M S Hashemi, Marc C Huisman, Jessica E Wijngaarden, Maarten Slebe, Daniela E Oprea-Lager, Gerben J C Zwezerijnen, Danielle Vugts, Ezgi B Ulas, Tanja D de Gruijl, Teodora Radonic, Suresh Senan, C Willemien Menke-van der Houven van O
Journal for ImmunoTherapy of Cancer.2024; 12(2): e007659. CrossRef
Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy
Pauline Hulo, Sophie Deshayes, Judith Fresquet, Anne-Laure Chéné, Stéphanie Blandin, Nicolas Boisgerault, Jean-François Fonteneau, Lucas Treps, Marc G Denis, Jaafar Bennouna, Delphine Fradin, Elvire Pons-Tostivint, Christophe Blanquart
Respiratory Research.2024;[Epub] CrossRef
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer
Ji Won Woo, Eun Kyung Han, Koung Jin Suh, Se Hyun Kim, Jee Hyun Kim, So Yeon Park
Breast Cancer Research and Treatment.2024; 207(2): 301. CrossRef
Transforming Lung Cancer Management: A Promising Case Study of Immune Checkpoint Inhibitor Success Following a Multidisciplinary Approach
Tadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, Tomohito Okano, Taro Yasuma, Esteban C. Gabazza, Hidenori Ibata, Tetsu Kobayashi
Diagnostics.2024; 14(19): 2159. CrossRef
Cryoablation plus chemotherapy regimen enhance anti-tumor immune response in a mouse model of Lewis lung cancer
Hua Duan, Li Yang, Xueni Fang, Shaohua Yan, Yang Cao, Bingli Qiao, Tian Zhou, Kaiwen Hu
International Journal of Hyperthermia.2024;[Epub] CrossRef
Increased Tumor Mutation Burden Levels and Sensitivity of Non–Small Cell Lung Cancer to PD-L1 Blockade—Reply
Biagio Ricciuti, Xinan Wang, Mark M. Awad
JAMA Oncology.2023; 9(4): 570. CrossRef
Add-On Effect of Hemagglutinating Virus of Japan Envelope Combined with Chemotherapy or Immune Checkpoint Inhibitor against Malignant Pleural Mesothelioma: An In Vivo Study
Kazuma Sakura, Masao Sasai, Soichiro Funaki, Yasushi Shintani, Meinoshin Okumura, Yasufumi Kaneda
Cancers.2023; 15(3): 929. CrossRef
Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data
WeiQing Venus So, David Dejardin, Eva Rossmann, Jehad Charo
Journal for ImmunoTherapy of Cancer.2023; 11(2): e006464. CrossRef
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
D. König, S. Savic Prince, S. Hayoz, P. Zens, S. Berezowska, W. Jochum, E. Stauffer, V. Braunersreuther, B. Trachsel, S. Thierstein, M. Mark, S. Schmid, A. Curioni-Fontecedro, A. Addeo, I. Opitz, M. Guckenberger, M. Früh, D.C. Betticher, H.-B. Ris, R. Stu
ESMO Open.2023; 8(4): 101595. CrossRef
Poliovirus receptor (PVR) mediates carboplatin-induced PD-L1 expression in non-small-cell lung cancer cells
Chen Fu, Zongcai Liu, Taixue An, Haixia Li, Xiumei Hu, Xin Li, Xinyao Liu, Danjuan Wu, Ruyi Zhang, Kui Li, Yurong Qiu, Haifang Wang
Biochimica et Biophysica Acta (BBA) - General Subjects.2023; 1867(10): 130439. CrossRef
Remarkable Response to Immune Checkpoint Inhibitor Monotherapy in an EGFR-Mutant Pulmonary Adenocarcinoma Patient With 0% Expression of PD-L1
Tetsuo Fujita, Hiroyuki Amano, Makoto Nakamura, Satoshi Hirano, Sukeyuki Nakamura
Journal of Thoracic Oncology.2023; 18(9): e93. CrossRef
Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer
Yu Zhao, Zhe Wang, Xiuhuan Shi, Ting Liu, Wenwen Yu, Xiubao Ren, Hua Zhao
Technology in Cancer Research & Treatment.2023;[Epub] CrossRef
The Role of Regulatory T Cells in Cancer Treatment Resistance
Anna Dąbrowska, Magdalena Grubba, Amar Balihodzic, Olga Szot, Bartosz Kamil Sobocki, Adrian Perdyan
International Journal of Molecular Sciences.2023; 24(18): 14114. CrossRef
Redirecting Chemotherapeutics to the Endoplasmic Reticulum Increases Tumor Immunogenicity and Potentiates Anti‐PD‐L1 Therapy
Yucheng Xiang, Liqiang Chen, Chendong Liu, Xiaoli Yi, Lian Li, Yuan Huang
Small.2022;[Epub] CrossRef
FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell–Mediated Bladder Cancer Immune Surveillance
Weiqiang Jing, Ganyu Wang, Zhiwei Cui, Gaozhong Xiong, Xin Jiang, Yue Li, Wushan Li, Bo Han, Shouzhen Chen, Benkang Shi
Cancer Research.2022; 82(1): 114. CrossRef
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
Daniel R. Principe, Suneel D. Kamath, Murray Korc, Hidayatullah G. Munshi
Pharmacology & Therapeutics.2022; 236: 108111. CrossRef
Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study
S. Park, J.-M. Sun, Y.-L. Choi, D. Oh, H.K. Kim, T. Lee, S.A. Chi, S.-H. Lee, Y.S. Choi, S.-H. Jung, M.-J. Ahn, Y.C. Ahn, K. Park, Y.M. Shim
ESMO Open.2022; 7(1): 100385. CrossRef
Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer
Jennifer L. Schehr, Nan Sethakorn, Zachery D. Schultz, Camila I. Hernandez, Rory M. Bade, Diego Eyzaguirre, Anupama Singh, David J. Niles, Leslie Henderson, Jay W. Warrick, Scott M. Berry, Kaitlin E. Sundling, David J. Beebe, Ticiana A. Leal, Joshua M. La
Biomarker Research.2022;[Epub] CrossRef
Translational Learnings in the Development of Chemo-Immunotherapy Combination to Bypass the Cold Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma
Hélène Kaplon
Frontiers in Oncology.2022;[Epub] CrossRef
Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC
Salman Hussain, Jitka Klugarova, Miloslav Klugar
Lung Cancer.2022; 170: 11. CrossRef
Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression
Kaiyue Ding, Minhan Yi, Hui Liang, Zhongkui Li, Yuan Zhang
Expert Review of Clinical Immunology.2022; 18(7): 759. CrossRef
Dual inhibition of TGFβ signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1
Tsung-Wei Chen, Wei-Ze Hung, Shu-Fen Chiang, William Tzu-Liang Chen, Tao-Wei Ke, Ji-An Liang, Chih-Yang Huang, Pei-Chen Yang, Kevin Chih-Yang Huang, K.S. Clifford Chao
Cancer Letters.2022; 543: 215795. CrossRef
SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer
Seung Ho Baek, Jee Hung Kim, Soong June Bae, Jung Hwan Ji, Yangkyu Lee, Joon Jeong, Yoon Jin Cha, Sung Gwe Ahn
Cancers.2022; 14(13): 3042. CrossRef
Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate
Taotao Zhou, Robert Mahn, Christian Möhring, Farsaneh Sadeghlar, Carsten Meyer, Marieta Toma, Barbara Kreppel, Markus Essler, Tim Glowka, Hanno Matthaei, Jörg C. Kalff, Christian P. Strassburg, Maria A. Gonzalez-Carmona
Frontiers in Oncology.2022;[Epub] CrossRef
Is there a place for chemotherapy in first line of treatment for metastatic NSCLC in era of immunotherapy?
D. I. Yudin, K. K. Laktionov
Medical alphabet.2022; (13): 18. CrossRef
The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer
Philipp Zens, Corina Bello, Amina Scherz, Michael von Gunten, Adrian Ochsenbein, Ralph A. Schmid, Sabina Berezowska
Modern Pathology.2022; 35(12): 1848. CrossRef
MicroRNAs and Drug Resistance in Non-Small Cell Lung Cancer: Where Are We Now and Where Are We Going
Roberto Cuttano, Miriam Kuku Afanga, Fabrizio Bianchi
Cancers.2022; 14(23): 5731. CrossRef
miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response
Roberto Cuttano, Tommaso Colangelo, Juliana Guarize, Elisa Dama, Maria Pia Cocomazzi, Francesco Mazzarelli, Valentina Melocchi, Orazio Palumbo, Elena Marino, Elena Belloni, Francesca Montani, Manuela Vecchi, Massimo Barberis, Paolo Graziano, Andrea Pasqui
Journal of Hematology & Oncology.2022;[Epub] CrossRef
PD‐1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma
Tahlia Scheinberg, Anna Lomax, Martin Tattersall, David Thomas, Geoff McCowage, Michael Sullivan, Rooshdiya Karim, Peter P. Luk, Annabelle Mahar, Fiona Bonar, Vivek A. Bhadri
Cancer Reports.2021;[Epub] CrossRef
PD‐L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non‐small cell lung cancer?
Aoran Dong, Yiming Zhao, Zhihua Li, Hai Hu
The Journal of Gene Medicine.2021;[Epub] CrossRef
Biomarkers predicting the response to chemotherapy and the prognosis in patients with esophageal squamous cell carcinoma
Seiya Inoue, Takahiro Yoshida, Takeshi Nishino, Masakazu Goto, Mariko Aoyama, Naoya Kawakita, Yota Yamamoto, Furukita Yoshihito, Hiromitsu Takizawa, Akira Tangoku
General Thoracic and Cardiovascular Surgery.2021; 69(3): 525. CrossRef
Patient-Reported Outcomes with Durvalumab by PD-L1 Expression and Prior Chemoradiotherapy-Related Variables in Unresectable Stage III Non-Small-Cell Lung Cancer
Marina C Garassino, Luis Paz-Ares, Rina Hui, Corinne Faivre-Finn, Alex Spira, David Planchard, Mustafa Özgüroğlu, Davey Daniel, David Vicente, Shuji Murakami, Corey Langer, Suresh Senan, David Spigel, Anna Rydén, Yiduo Zhang, Cathy O'Brien, Phillip A Denn
Future Oncology.2021; 17(10): 1165. CrossRef
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
S. Sugawara, J.-S. Lee, J.-H. Kang, H.R. Kim, N. Inui, T. Hida, K.H. Lee, T. Yoshida, H. Tanaka, C.-T. Yang, M. Nishio, Y. Ohe, T. Tamura, N. Yamamoto, C.-J. Yu, H. Akamatsu, Y. Namba, N. Sumiyoshi, K. Nakagawa
Annals of Oncology.2021; 32(9): 1137. CrossRef
Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
Chang Hyun Nam, Jaemoon Koh, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
The Korean Journal of Internal Medicine.2021; 36(4): 975. CrossRef
Methylseleninic acid overcomes programmed death‐ligand 1‐mediated resistance of prostate cancer and lung cancer
Wenli Hu, Yurong Ma, Chong Zhao, Shutao Yin, Hongbo Hu
Molecular Carcinogenesis.2021; 60(11): 746. CrossRef
Immunological Status of Bladder Cancer Patients Based on Urine Leukocyte Composition at Radical Cystectomy
Elisabet Cantó, Óscar Rodríguez Faba, Carlos Zamora, Maria Mulet, Maria Soledad Garcia-Cuerva, Ana Palomino, Georgia Anguera, Alberto Breda, Pablo Maroto, Sílvia Vidal
Biomedicines.2021; 9(9): 1125. CrossRef
Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions
Daun Jung, Young Seok Baek, In Jee Lee, Ki Yeon Kim, Heejoo Jang, Sohyun Hwang, Jieun Jung, Yong-wha Moon, Kyung-Soon Park, Yong-Soo Choi, Hee Jung An
Journal of Experimental & Clinical Cancer Research.2021;[Epub] CrossRef
Prognostic significance of T‐cell–inflamed gene expression profile and PD‐L1 expression in patients with esophageal cancer
Torben Steiniche, Sun Young Rha, Hyun Cheol Chung, Jeanette Baehr Georgsen, Morten Ladekarl, Marianne Nordsmark, Marie Louise Jespersen, Hyo Song Kim, Hyunki Kim, Carly Fein, Laura H. Tang, Ting Wu, Matthew J. Marton, Senaka Peter, David P. Kelsen, Geoffr
Cancer Medicine.2021; 10(23): 8365. CrossRef
A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody
Eun Ji Lee, Gun-Young Jang, Sung Eun Lee, Ji won Lee, Hee Dong Han, Yeong-Min Park, Tae Heung Kang
Immunology Letters.2021;[Epub] CrossRef
Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor‐infiltrating immune cells and survival
Lei Tu, Renguo Guan, Hanting Yang, Yu Zhou, Weifeng Hong, Liheng Ma, Guangzhe Zhao, Min Yu
International Journal of Cancer.2020; 147(2): 423. CrossRef
Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis
Jiahang Mo, Xiao Hu, Lihu Gu, Bangsheng Chen, Parikshit Asutosh Khadaroo, Zefeng Shen, Lei Dong, Yuqi Lv, Marylin Nyaradzo Chitumba, Jiequan Liu
World Journal of Surgical Oncology.2020;[Epub] CrossRef
Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
Kathrin Gennen, Lukas Käsmann, Julian Taugner, Chukwuka Eze, Monika Karin, Olarn Roengvoraphoj, Jens Neumann, Amanda Tufman, Michael Orth, Simone Reu, Claus Belka, Farkhad Manapov
Radiation Oncology.2020;[Epub] CrossRef
PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer
Jaanika Narits, Hannes Tamm, Jana Jaal
Clinical and Translational Radiation Oncology.2020; 22: 83. CrossRef
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
Yun Liang, Minghua Yu, Caiyun Zhou, Xiaojun Zhu
Diagnostic Pathology.2020;[Epub] CrossRef
Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench
Rui Jin, Jing Zhao, Lexin Xia, Qin Li, Wen Li, Ling Peng, Yang Xia
Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef
Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma
Dovile Zilenaite, Allan Rasmusson, Renaldas Augulis, Justinas Besusparis, Aida Laurinaviciene, Benoit Plancoulaine, Valerijus Ostapenko, Arvydas Laurinavicius
Frontiers in Oncology.2020;[Epub] CrossRef
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Lorenzo Galluzzi, Juliette Humeau, Aitziber Buqué, Laurence Zitvogel, Guido Kroemer
Nature Reviews Clinical Oncology.2020; 17(12): 725. CrossRef
Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression
Malene Støchkel Frank, Uffe Bødtger, Asbjørn Høegholm, Inger Merete Stamp, Julie Gehl
Lung Cancer.2020; 149: 23. CrossRef
The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
Giuseppe Lamberti, Monia Sisi, Elisa Andrini, Arianna Palladini, Francesca Giunchi, Pier-Luigi Lollini, Andrea Ardizzoni, Francesco Gelsomino
Cancers.2020; 12(11): 3129. CrossRef
The Dichotomous Role of Bone Marrow Derived Cells in the Chemotherapy-Treated Tumor Microenvironment
Avital Vorontsova, Tal Kan, Ziv Raviv, Yuval Shaked
Journal of Clinical Medicine.2020; 9(12): 3912. CrossRef
Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non–small Cell Lung Cancer Recurrence
Max Lacour, Stefanie Hiltbrunner, Seok-Yun Lee, Alex Soltermann, Elisabeth Jane Rushing, Davide Soldini, Walter Weder, Alessandra Curioni-Fontecedro
Clinical Lung Cancer.2019; 20(5): 391. CrossRef
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
Hyojin Kim, Jin-Haeng Chung
Journal of Pathology and Translational Medicine.2019; 53(4): 199. CrossRef

11,539 View
483 Download
61 Web of Science
56 Crossref

Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer: Min-Young Lee, Bo Mi Ku, Hae Su Kim, Ji Yun Lee, Sung Hee Lim, Jong-Mu Sun, Se-Hoon Lee, Keunchil Park, Young Lyun Oh, Mineui Hong, Han-Sin Jeong, Young-Ik Son, Chung-Hwan Baek, Myung-Ju Ahn; Cancer Res Treat. 2017;49(4):906-914. Published online December 26, 2016; DOI: https://doi.org/10.4143/crt.2016.424

Abstract PDF PubReader ePub

Purpose
Papillary thyroid carcinomas (PTCs) frequently involve genetic alterations. The objective of this study was to investigate genetic alterations and further explore the relationships between these genetic alterations and clinicopathological characteristics in a high-recurrence risk (node positive, N1) PTC group.
Materials and Methods
Tumor tissue blocks were obtained from 240 surgically resected patients with histologically confirmed stage III/IV (pT3/4 or N1) PTCs. We screened gene fusions using NanoString’s nCountertechnology and mutational analysiswas performed by directDNA sequencing.Data describing the clinicopathological characteristics and clinical courses were retrospectively collected.
Results
Of the 240 PTC patients, 207 (86.3%) had at least one genetic alteration, including BRAF mutation in 190 patients (79.2%), PIK3CA mutation in 25 patients (10.4%), NTRK1/3 fusion in six patients (2.5%), and RET fusion in 24 patients (10.0%). Concomitant presence of more than two genetic alterations was seen in 36 patients (15%). PTCs harboring BRAF mutation were associated with RET wild-type expression (p=0.001). RET fusion genes have been found to occur with significantly higher frequency in N1b stage patients (p=0.003) or groups of patients aged 45 years or older (p=0.031); however, no significant correlation was found between other genetic alterations. There was no trend toward favorable recurrence-free survival or overall survival among patients lacking genetic alterations.
Conclusion
In the selected high-recurrence risk PTC group, most patients had more than one genetic alteration. However, these known alterations could not entirely account for clinicopathological features of high-recurrence risk PTC.

Citations

Citations to this article as recorded by

Role of contrast-enhanced ultrasound with time-intensity curve analysis about thyroid nodule and parenchyma for differentiating BRAF V600E mutation status
Zhipeng Hu, Rong Xue, Zhixi Liu, Liang Liu, Zheli Gong
PeerJ.2025; 13: e19006. CrossRef
BRAF V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma
Nobuyuki Bandoh, Takashi Goto, Yasutaka Kato, Akinobu Kubota, Shota Sakaue, Ryuhei Takeda, Shuto Hayashi, Misaki Hayashi, Shogo Baba, Tomomi Yamaguchi-Isochi, Hiroshi Nishihara, Hajime Kamada
Asian Journal of Surgery.2024; 47(1): 413. CrossRef
FHL1: A novel diagnostic marker for papillary thyroid carcinoma
Yeting Zeng, Dehua Zeng, Xingfeng Qi, Hanxi Wang, Xuzhou Wang, Xiaodong Dai, Lijuan Qu
Pathology International.2024; 74(9): 520. CrossRef
Rearranged During Transfection Rearrangement Detection by Fluorescence In Situ Hybridization Compared With Other Techniques in NSCLC
Anne Mc Leer, Julie Mondet, Nelly Magnat, Mailys Mersch, Diane Giovannini, Camille Emprou, Anne-Claire Toffart, Nathalie Sturm, Sylvie Lantuéjoul, David Benito
JTO Clinical and Research Reports.2024; 5(12): 100714. CrossRef
Essential news for clinical practice—thyroid cancer
Barbara Kiesewetter, Ladislaia Wolff, Markus Raderer
memo - Magazine of European Medical Oncology.2023; 16(1): 47. CrossRef
A new paradigm for epidermal growth factor receptor expression exists in PTC and NIFTP regulated by microRNAs
Abeer Al-Abdallah, Iman Jahanbani, Rola H. Ali, Nabeel Al-Brahim, Jeena Prasanth, Bashayer Al-Shammary, Maie Al-Bader
Frontiers in Oncology.2023;[Epub] CrossRef
NanoString in the screening of genetic abnormalities associated with thyroid cancer
Elisabetta Macerola, Anello Marcello Poma, Fulvio Basolo
Seminars in Cancer Biology.2022; 79: 132. CrossRef
The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations
Steve Duff, Francesca Bargiacchi, Chelsea Norregaard, Melanie Brener, Erin Sullivan
Journal of Managed Care & Specialty Pharmacy.2022; 28(2): 218. CrossRef
Thyroid cancer incidence disparities among ethnic Asian American populations, 1990–2014
Alice W. Lee, Roy A. Mendoza, Shehla Aman, Robert Hsu, Lihua Liu
Annals of Epidemiology.2022; 66: 28. CrossRef
Analytical Accuracy of RET Fusion Detection by Break-Apart Fluorescence In Situ Hybridization
Jessica A. Baker, Anthony N. Sireci, Narasimha Marella, Holly Kay Cannon, Tyler J. Marquart, Timothy R. Holzer, Leslie O'Neill Reising, Joel D. Cook, Sameera R. Wijayawardana, Juraj Bodo, Eric D. Hsi, Andrew E. Schade, Gerard J. Oakley
Archives of Pathology & Laboratory Medicine.2022; 146(3): 351. CrossRef
Intratumoral Genetic Heterogeneity in Papillary Thyroid Cancer: Occurrence and Clinical Significance
Laura Fugazzola, Marina Muzza, Gabriele Pogliaghi, Mario Vitale
Cancers.2020; 12(2): 383. CrossRef
The stress-activated protein kinase pathway and the expression of stanniocalcin-1 are regulated by miR-146b-5p in papillary thyroid carcinogenesis
Abeer Al-Abdallah, Iman Jahanbani, Heba Mehdawi, Rola H Ali, Nabeel Al-Brahim, Olusegun Mojiminiyi
Cancer Biology & Therapy.2020; 21(5): 412. CrossRef
Risk Stratification Using a Novel Genetic Classifier IncludingPLEKHS1Promoter Mutations for Differentiated Thyroid Cancer with Distant Metastasis
Chan Kwon Jung, Seung-Hyun Jung, Sora Jeon, Young Mun Jeong, Yourha Kim, Sohee Lee, Ja-Seong Bae, Yeun-Jun Chung
Thyroid.2020; 30(11): 1589. CrossRef
Prediction of cervical lymph node metastasis with contrast-enhanced ultrasound and association between presence of BRAFV600E and extrathyroidal extension in papillary thyroid carcinoma
Jia Zhan, Long-hui Zhang, Qing Yu, Chao-lun Li, Yue Chen, Wen-Ping Wang, Hong Ding
Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef
Clinical significance of eukaryotic translation initiation factor 5A2 in papillary thyroid cancer
Hongmei Zhang, Kejun Zhang, Liang Ning, Dong Chen, Fengyun Hao, Peng Li
Bioengineered.2020; 11(1): 1325. CrossRef
High Preponderance of BRAF V600E Mutation in Papillary Thyroid Carcinoma Among Filipinos: A Clinicopathologic Study
Gerard Anthony M. Espiritu, Joemari T. Malana, Arlie Jean Grace V. Dumasis, Daphne C. Ang
Journal of Global Oncology.2019; (5): 1. CrossRef
PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis
Ali Alqahtani, Hazem S. K. Ayesh, Hafez Halawani
Cancers.2019; 12(1): 93. CrossRef
Targeted next‑generation sequencing of cancer‑related genes in thyroid carcinoma: A single institution's experience
Nobuyuki Bandoh, Toshiaki Akahane, Takashi Goto, Michihisa Kono, Haruyuki Ichikawa, Takahiro Sawada, Tomomi Yamaguchi, Hiroshi Nakano, Yumiko Kawase, Yasutaka Kato, Hajime Kamada, Yasuaki Harabuchi, Kazuo Shimizu, Hiroshi Nishihara
Oncology Letters.2018;[Epub] CrossRef
Niclosamide induces apoptosis through mitochondrial intrinsic pathway and inhibits migration and invasion in human thyroid cancer in vitro
Kai Yu, Tingting Wang, Yujue Li, Chun Wang, Xia Wang, Mei Zhang, Yongmei Xie, Shuangqing Li, Zhenmei An, Tinghong Ye
Biomedicine & Pharmacotherapy.2017; 92: 403. CrossRef

11,365 View
371 Download
20 Web of Science
19 Crossref

Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea: Hee Kyung Kim, Jun Soo Ham, Seonggyu Byeon, Kwai Han Yoo, Ki Sun Jung, Haa-Na Song, Jinhyun Cho, Ji Yun Lee, Sung Hee Lim, Hae Su Kim, Ji-Yeon Kim, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Se Kyung Lee, Soo Youn Bae, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park; Cancer Res Treat. 2016;48(4):1382-1388. Published online March 11, 2016; DOI: https://doi.org/10.4143/crt.2015.423

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to assess the tumor characteristics and long-term clinical outcomes of adjuvant treatments after surgery with a curative aim for patients with breast cancer who are 65 years and older. Materials and Methods Patients with breast cancer who underwent curative surgery from 2000 to 2009 were analyzed (n=4,388). Tumor characteristics and survival outcome were compared by dividing the patients into two age groups (< 65 and ≥ 65 years old). The Kaplan-Meier method was used for comparison of survival rates by log-rank test, and a Cox regression model was used to examine the effect of variables.
Results
Among 4,388 patients with invasive breast cancer, 317 patients (7.2%) were 65 years or older and the median age of all patients was 47 years (range, 18 to 91 years). Tumor characteristics were similar between the two age groups, but the older patients were treated less often with adjuvant treatments. During a median follow-up period of 122 months, recurrence-free survival (RFS) was equivalent for patients 65 years and older compared to younger patients, but significantly worse in overall survival (OS) and breast cancer–specific survival (BCSS) (5-year OS, 94.3% vs. 90.5%; p < 0.001 and 5-year BCSS, 94.7% vs. 91.8%; p=0.031). In the multivariate model, age ≥ 65 years old was identified as an independent risk factor for OS and RFS. Conclusion Elderly breast cancer appeared to have worse outcomes with very low prevalence in Korea, despite similar tumor characteristics. More active adjuvant therapies would have a role for aggressive subtypes for fit, elderly patients.

Citations

Citations to this article as recorded by

HISTOPATHOLOGICAL AND BIOLOGICAL BEHAVIOR OF BREAST CANCER IN ELDERLY KURDISH WOMEN
Kamal Saeed, Shewaz Salih
JOURNAL OF SULAIMANI MEDICAL COLLEGE.2023; 13(4): 11. CrossRef
Analysis of the tumor characteristics in young age breast cancer patients using collaborative stage data of the Korea Central Cancer Registry
Junyup Kim, Seri Hong, Jae Jun Lee, Young-Joo Won, Eun Sook Lee, Han-Sung Kang, Seeyoun Lee, Jai Hong Han, Eun-Gyeong Lee, Heein Jo, Hyun Hee Kim, So-Youn Jung
Breast Cancer Research and Treatment.2021; 187(3): 785. CrossRef
Survival outcomes in elderly Taiwanese women according to breast cancer subtype and lymph node status: A single-center retrospective study
Kung-Hung Lin, Huan-Ming Hsu, Kuo-Feng Hsu, Chi-Hong Chu, Zhi-Jie Hong, Chun-Yu Fu, Yu-Ching Chou, Golshan Mehra, Ming-Shen Dai, Jyh-Cherng Yu, Guo-Shiou Liao, Jason Chia-Hsun Hsieh
PLOS ONE.2021; 16(12): e0261258. CrossRef
Could lymph node evaluation be eliminated in nearly 50% of women with early stage ER/PR positive breast cancer?
Juan Ruiz, Gerson Maldonado, Elizabeth Ablah, Hayrettin Okut, Jared Reyes, Karson Quinn, Patty L. Tenofsky
The American Journal of Surgery.2020; 220(6): 1417. CrossRef
Overall survival of elderly patients with breast cancer is not related to breast-cancer specific survival: A single institution experience in Japan
Haruko Takuwa, Wakako Tsuji, Fumiaki Yotsumoto
Breast Disease.2018; 37(4): 177. CrossRef
Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting
Chiara Mandoj, Laura Pizzuti, Domenico Sergi, Isabella Sperduti, Marco Mazzotta, Luigi Di Lauro, Antonella Amodio, Silvia Carpano, Anna Di Benedetto, Claudio Botti, Francesca Ferranti, Anna Antenucci, Maria Gabriella D’Alessandro, Paolo Marchetti, Silveri
Journal of Translational Medicine.2018;[Epub] CrossRef
Do site and type of metastasis in breast cancer show a changing pattern with increased age? A cross comparison of clinicopathological characteristics between age groups
Majid Akrami, Afrooz Sepahdar, Peyman Arasteh, Sedigheh Tahmasebi, Vahid Zangouri, Azam Askari, Babak Pezeshki, Abdolrasoul Talei
World Journal of Surgical Oncology.2018;[Epub] CrossRef
Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice
Jessemae L. Welsh, Tanya L. Hoskin, Courtney N. Day, Elizabeth B. Habermann, Matthew P. Goetz, Judy C. Boughey
Annals of Surgical Oncology.2017; 24(10): 2881. CrossRef
Combination of 125I brachytherapy and chemotherapy for unresectable recurrent breast cancer
Qixing Tan, Qinghong Qin, Weiping Yang, Bin Lian, Qinguo Mo, Changyuan Wei
Medicine.2016; 95(44): e5302. CrossRef

12,896 View
156 Download
8 Web of Science
9 Crossref

Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study: Myung Ah Lee, Eun Kyung Cho, Sung Yong Oh, Joong Bae Ahn, Ji Yun Lee, Burke Thomas, Hun Jung, Jong Gwang Kim; Cancer Res Treat. 2016;48(4):1420-1428. Published online February 12, 2016; DOI: https://doi.org/10.4143/crt.2015.309

Abstract PDF PubReader ePub

Purpose
This study reported patient outcomes of chemotherapy-induced nausea and vomiting (CINV) prophylaxis for highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) regimens and evaluated its adherence to acute-phase CINV prophylaxis in the Korean population subset of the Pan Australasian Chemotherapy Induced Emesis burden of illness (PrACTICE) study. Materials and Methods This subgroup analysis evaluated 158 Korean patients receiving HEC or MEC and compared the data (wherever possible) with that of 648 patients from the Asia-Pacific (AP) region. Study endpoints included evaluation of primary CINV prophylaxis and adherence to acutephase CINV prophylaxis in cycle 1 (American Society of Clinical Oncology [ASCO] Quality Oncology Practice Initiative [QOPI]).
Results
In South Korea and the AP, a 5-hydroxytryptamine-3 receptor antagonist (5HT3-RA) prophylaxis for the acute phase was administered to 79/80 patients (98.8%) for HEC and 70/71 patients (98.6%) for MEC regimens (QOPI-1). Triple regimen (corticosteroid–5HT3-RA–neurokinin 1-RA) was initiated in 46/80 patients (57.5%) for prophylaxis of acute CINV in cycle 1 of HEC (QOPI-3). Double regimen (corticosteroid–5HT3-RA, with or within NK1-RA) was initiated in 61/71 patients (83.1%) for control of acute CINV in cycle 1 of MEC a(QOPI-2). Conclusion Active management of CINV is necessary in cycle 1 of HEC in South Korea, despite higher rates than the AP region. Adherence to the international guidelines for CINV prophylaxis requires attention in the acute phase in cycle 1 of the HEC regimen.

Citations

Citations to this article as recorded by

Adherence to antiemetic guidelines in solid cancer patients receiving highly emetogenic chemotherapy in Korea
Ryugyoung Lee, Minhee Ku, Nam Kyung Je
Supportive Care in Cancer.2024;[Epub] CrossRef
Chemotherapy-Associated Nausea and Vomiting
Kelvin Mogesa Manyega, Benjamin Nasara Joseph, Okunlola Charity Rotkangmwa, Maxwell P. Dapar
Annals of African Medicine.2022; 21(2): 124. CrossRef
Expert Consensus on Effective Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective
Ashok K. Vaid, Sudeep Gupta, Dinesh C. Doval, Shyam Agarwal, Shona Nag, Poonam Patil, Chanchal Goswami, Vikas Ostwal, Sagar Bhagat, Saiprasad Patil, Hanmant Barkate
Frontiers in Oncology.2020;[Epub] CrossRef
Construção e avaliação de bundle frente ao extravasamento de antineoplásicos: estudo metodológico
João Marcos Alves Melo, Patrícia Peres de Oliveira, Andrea Bezerra Rodrigues, Raíssa Silva Souza, Deborah Franscielle da Fonseca, Thaís Fonseca Gontijo, Edilene Aparecida Araújo da Silveira
Acta Paulista de Enfermagem.2020;[Epub] CrossRef
A cost-utility analysis of risk model-guided versus physician’s choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach
Kednapa Thavorn, Doug Coyle, Jeffrey S. Hoch, Lisa Vandermeer, Sasha Mazzarello, Zhou Wang, George Dranitsaris, Dean Fergusson, Mark Clemons
Supportive Care in Cancer.2017; 25(8): 2505. CrossRef

10,672 View
154 Download
5 Web of Science
5 Crossref

Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma: Hae Su Kim, Ji Yun Lee, Sung Hee Lim, Keunchil Park, Jong-Mu Sun, Young Hyeh Ko, Chung-Hwan Baek, Young-ik Son, Han Sin Jeong, Yong Chan Ahn, Min-Young Lee, Mineui Hong, Myung-Ju Ahn; Cancer Res Treat. 2016;48(2):527-536. Published online September 15, 2015; DOI: https://doi.org/10.4143/crt.2015.249

Abstract PDF PubReader ePub

Purpose
Oropharyngeal squamous cell carcinoma (OSCC) has been recognized as an immunosuppressive disease. Various mechanisms have been proposed for immune escape, including dysregulation of immune checkpoints such as the PD-1:PD-L1 pathway. We investigated the expression of programmed cell death-ligand 1 (PD-L1) in HPV-negative and HPV-positive OSCC to determine its prevalence and prognostic relevance.
Materials and Methods
Using immunohistochemistry, 133 cases of OSCC were evaluated for expression of PD-L1. Formalin-fixed paraffin-embedded tumor samples were stained with monoclonal antibody (clone 5H1) to PD-L1. PD-L1 positivity was defined as membrane staining in ≥20% of tumor cells. Correlations between PD-L1 expression and HPV status and survival parameters were analyzed.
Results
Of the 133 patients, 68% showed PD-L1 expression, and 67% of patients were positive for p16 expression by immunohistochemistry. No significant difference in PD-L1 expression was observed between HPV(-) and HPV(+) tumors (61% vs. 71%, p=0.274). No significant difference in age, gender, smoking history, location of tumor origin, or stage was observed according to PD-L1 status. With a median follow-up period of 44 months, older age (≥65) (p=0.017) and T3-4 stage (p<0.001) were associated with poor overall survival (OS), whereas PD-L1 expression did not affect OS in univariate and multivariate analysis.
Conclusion
PD-L1 expression was observed in the majority of OSCC patients regardless of HPV status. Further large prospective studies are required to determine the role of PD-L1 expression as a prognostic or predictive biomarker, and clinical studies of immune checkpoint inhibitors in OCSS are warranted regardless of HPV status.

Citations

Citations to this article as recorded by

A bibliometric analysis of immune response in oral cancer
Rongrong Zhang, Runying Guo, Yuqi Xin, Qingkun Jiang, Jiaxuan Qiu
Discover Oncology.2025;[Epub] CrossRef
HPV frequency in oral cavity and oropharynx cancers and its association with immune checkpoint inhibitors
Hayriye Tatlı Doğan, Mustafa Tahtacı
Türk Tıp Dergisi.2025; 10(1): 1. CrossRef
Treatment Outcomes of Squamous Cell Carcinoma of the Soft Palate and the Prognostic Significance of HPV/p16 Status
Meng‐hua Li, Xing Zhang, Feng‐jiao Li, Xian‐lu Gao, Shi‐da Yan, Qiao‐hong Lin, Xi‐yuan Li, Jian Meng, Ying Zhang, Shi‐ting Zhang, Shu‐wei Chen, Ming Song
Head & Neck.2025;[Epub] CrossRef
Prognostic role of PD-L1 expression in head and neck squamous cell carcinoma: An institutional experience from India
Pooja Sharma Kala, Naveen Thapliyal, Bhawna Pant, Nitin Sharma, Hari Shankar Pandey
Pathology - Research and Practice.2024; 254: 155133. CrossRef
Référentiel national de traitement des carcinomes épidermoïdes des voies aérodigestives supérieures – Principes généraux de traitement
Béatrix Barry, Gilles Dolivet, Florian Clatot, Florence Huguet, Cyril Abdeddaim, Bertrand Baujat, Nicolas Blanchard, Gilles Calais, Xavier Carrat, Anne Chatellier, Florence Coste, Didier Cupissol, Philippe Cuvelier, Erwan De Mones Del Pujol, Sophie Deneuv
Bulletin du Cancer.2024; 111(4): 393. CrossRef
PD-L1 expression in head and neck squamous cell carcinoma and its clinical significance: A prospective observational study from a tertiary care centre
Sindhu Kilaru, Soumya Surath Panda, Lalatendu Moharana, Debahuti Mohapatra, Satya Sundar G. Mohapatra, Adyakinkar Panda, Spoorthy Kolluri, Suma Devaraj, Ananya Kabi, Bharat Das, Ghanashyam Biswas
Journal of Cancer Research and Therapeutics.2024; 20(1): 46. CrossRef
Histologic and Genomic Analysis of Conjunctival SCC in African and American Cohorts Reveal UV Light and HPV Signatures and High Tumor Mutation Burden
Frederico O. Gleber-Netto, Priyadharsini Nagarajan, Oded Sagiv, Curtis R. Pickering, Neil Gross, Jing Ning, Melisachew M. Yeshi, Yonas Mitku, Michael T. Tetzlaff, Bita Esmaeli
Investigative Opthalmology & Visual Science.2024; 65(4): 24. CrossRef
Considerable interlaboratory variation in PD‐L1 positivity for head and neck squamous cell carcinoma in the Netherlands— A nationwide evaluation study
Maaike Anna Hempenius, Bregje M Koomen, Ivette A G Deckers, Sjoukje F Oosting, Stefan M Willems, Bert van der Vegt
Histopathology.2024; 85(1): 133. CrossRef
The Role of Estrogen and Estrogen Receptors in Head and Neck Tumors
Jacqueline-Katrin Kranjčević, Josipa Čonkaš, Petar Ozretić
Cancers.2024; 16(8): 1575. CrossRef
PD-L1 Expression and Its Association With p16 in Head and Neck Squamous Cell Carcinoma in Southwestern Uganda
Rita Nabulya, Raymond Atwine, Brian Ssenkumba, Yekosani Mitala, Jamilah Nabukenya
Pathology and Laboratory Medicine International.2024; Volume 16: 1. CrossRef
High‐risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: Uncovering mechanisms of immune evasion and therapeutic prospects
Irene Lo Cigno, Federica Calati, Carlo Girone, Marta Catozzo, Marisa Gariglio
Journal of Medical Virology.2024;[Epub] CrossRef
PD-L1 immunohistochemical expression considering HPV status in oropharyngeal squamous cell carcinoma
Raíssa Soares dos ANJOS, Marianne de Vasconcelos CARVALHO, Rayanna Thayse Florêncio COSTA, Belmiro Cavalcanti do Egito VASCONCELOS, Sandra Lúcia Dantas MORAES, Eduardo Piza PELLIZZER
Brazilian Oral Research.2024;[Epub] CrossRef
PD-1 and PD-L1 Expression Levels as a Potential Biomarker of Chronic Rhinosinusitis and Head and Neck Cancers
Katarzyna Malinowska, Andrzej Kowalski, Anna Merecz-Sadowska, Milena Paprocka-Zjawiona, Przemysław Sitarek, Tomasz Kowalczyk, Hanna Zielińska-Bliźniewska
Journal of Clinical Medicine.2023; 12(5): 2033. CrossRef
Immunotherapy in oral cancer: Review
Despoina Papaioannou, Spyridoula Petsali, Alida Ndreou, Fani Akritidou, Vasileios Zisis, Dimitrios Kavvadas, Athanasios Poulopoulos, Sofia Karachrysafi, Dimitrios Andreadis
Balkan Journal of Dental Medicine.2023; 27(3): 129. CrossRef
Programmed Death Ligand-1 Combined Positive Score Concordance and Interrater Reliability in Primary Tumors and Synchronous Lymph Node Metastases in Resected Cases of p16+ Oropharyngeal Squamous Cell Carcinoma
Amandeep Kaur, Kristine Kuchta, William Watkin, Megan Sullivan, Lin Liu, Pouya Jamshidi, Nick Campbell, Bruce Brockstein, Ajit Paintal
Archives of Pathology & Laboratory Medicine.2023; 147(4): 442. CrossRef
Expression of immune checkpoint protein in oral squamous cell carcinoma and its clinicopathological correlation: A tertiary care center cross-sectional study
Sonal Ratnakar, Madhu Kumar, Malti K. Maurya, Sumaira Qayoom, Mala Sagar, Suresh Babu, Vijay Kumar
Journal of Oral and Maxillofacial Pathology.2023; 27(3): 597. CrossRef
Commentary on “Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma”
Juan Francisco Peña-Cardelles, José Ernesto Moro-Rodríguez, José Luís Cebrián-Carretero, José Juan Pozo-Kreilinger
Open Medicine.2022; 17(1): 227. CrossRef
Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis
Ramy R. Saleh, Jordan L. Scott, Nicholas Meti, Danielle Perlon, Rouhi Fazelzad, Alberto Ocana, Eitan Amir
Molecular Diagnosis & Therapy.2022; 26(2): 153. CrossRef
Immunotherapy for head and neck cancer: Present and future
Morena Fasano, Carminia Maria Della Corte, Raimondo Di Liello, Giuseppe Viscardi, Francesca Sparano, Maria Lucia Iacovino, Fernando Paragliola, Antonio Piccolo, Stefania Napolitano, Giulia Martini, Floriana Morgillo, Salvatore Cappabianca, Fortunato Ciard
Critical Reviews in Oncology/Hematology.2022; 174: 103679. CrossRef
Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma
Sebastian Blatt, Maximilian Krüger, Constantin Rump, Stefanie Zimmer, Keyvan Sagheb, Julian Künzel, Afsheen Raza
PLOS ONE.2022; 17(5): e0269136. CrossRef
Expression of PD-L1 is HPV/P16-independent in oral squamous cell carcinoma
Kit Kitichotkul, Nirush Lertprasertsuke, Sompid Kintarak, Surawut Pongsiriwet, Warit Powcharoen, Anak Iamaroon
Heliyon.2022; 8(10): e10667. CrossRef
Survival Outcomes of Complete Pulmonary Metastasectomy for Head and Neck Squamous Cell Carcinomas
Hiroaki Kuroda, Shin Koyama, Mingyon Mun, Jun Nakajima, Kazuhito Funai, Ichiro Yoshino, Yoshikane Yamauchi, Masafumi Kawamura
Cancer Management and Research.2022; Volume 14: 3095. CrossRef
Expression of PD-L1 is HPV/P16-Independent in Oral Squamous Cell Carcinoma
Kit Kitichotkul, Nirush Lertprasertsuke, Sompid Kintarak, Surawut Pongsiriwet, Warit Powcharoen, Anak Iamaroon
SSRN Electronic Journal .2022;[Epub] CrossRef
CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma
Songtao Zhang, Qiujie Yan, Song Wei, Xiaobo Feng, Miaomiao Xue, Lina Liu, Jili Cui, Yuanyuan Zhang
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2021; 132(2): 202. CrossRef
PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis
Yuan Qin, Jiaochen Luan, Xiang Zhou, Ying Li
Bioscience Reports.2021;[Epub] CrossRef
Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors
Parmida Sadat Pezeshki, Pouya Mahdavi Sharif, Nima Rezaei
Expert Opinion on Biological Therapy.2021; 21(12): 1575. CrossRef
PD-L1 TESTING AND IMMUNOTHERAPY SELECTION – EARLY LABORATORY EXPERIENCE AND ITS POTENTIAL ROLE IN HEAD AND NECK CANCER MANAGEMENT
Bancu Bancu, Richard Cowan, Anshuman Chaturvedi
Archive of Clinical Cases.2021; 8(1): 14. CrossRef
Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus
Huanhuan Wang, Qin Zhao, Yuyu Zhang, Qihe Zhang, Zhuangzhuang Zheng, Shiyu Liu, Zijing Liu, Lingbin Meng, Ying Xin, Xin Jiang
Frontiers in Immunology.2021;[Epub] CrossRef
The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis
Emily Clarke, Jesper Grau Eriksen, Sarah Barrett
Acta Oncologica.2021; 60(11): 1534. CrossRef
Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma
Alexander A. Strait, Rachel A. Woolaver, Spencer C. Hall, Christian D. Young, Sana D. Karam, Antonio Jimeno, Yan Lan, David Raben, Jing H. Wang, Xiao-Jing Wang
Communications Biology.2021;[Epub] CrossRef
Commentary on 'Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis' (He et al., (2020) Archives of Oral Biology, 114, 104717)
Juan Francisco Peña-Cardelles, José Ernesto Moro-Rodríguez, José Luís Cebrián-Carretero, José Juan Pozo-Kreilinger
Archives of Oral Biology.2021; 132: 105274. CrossRef
Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
Kimberly M. Burcher, Jeffrey W. Lantz, Elena Gavrila, Arianne Abreu, Jack T. Burcher, Andrew T. Faucheux, Amy Xie, Clayton Jackson, Alexander H. Song, Ryan T. Hughes, Thomas Lycan, Paul M. Bunch, Cristina M. Furdui, Umit Topaloglu, Ralph B. D’Agostino, We
Cancers.2021; 13(22): 5733. CrossRef
Prognostic Significance of PD-L1 Expression In Patients With Primary Oropharyngeal Squamous Cell Carcinoma: A Meta-Analysis
Jerry Polesel, Anna Menegaldo, Giancarlo Tirelli, Vittorio Giacomarra, Roberto Guerrieri, Lorena Baboci, Mariateresa Casarotto, Valentina Lupato, Giuseppe Fanetti, Paolo Boscolo-Rizzo, Elisabetta Fratta
Frontiers in Oncology.2021;[Epub] CrossRef
Tumor Immunity and Immunotherapy for HPV-Related Cancers
Achraf A. Shamseddine, Bharat Burman, Nancy Y. Lee, Dmitriy Zamarin, Nadeem Riaz
Cancer Discovery.2021; 11(8): 1896. CrossRef
An update of knowledge on PD‐L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives
Daniel Lenouvel, Miguel Ángel González‐Moles, Asmae Talbaoui, Pablo Ramos‐García, Lucía González‐Ruiz, Isabel Ruiz‐Ávila, José Antonio Gil‐Montoya
Oral Diseases.2020; 26(3): 511. CrossRef
A treatise on endothelial biology and exosomes: homage to Theresa Maria Listowska Whiteside
N. Ludwig, M. T. Lotze
HNO.2020; 68(2): 71. CrossRef
PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva
Bastian Czogalla, Deborah Pham, Fabian Trillsch, Miriam Rottmann, Julia Gallwas, Alexander Burges, Sven Mahner, Thomas Kirchner, Udo Jeschke, Doris Mayr, Elisa Schmoeckel
Journal of Cancer Research and Clinical Oncology.2020; 146(3): 569. CrossRef
Prognostic impact of PD-L1 in oropharyngeal cancer after primary curative radiotherapy and relation to HPV and tobacco smoking
Jacob K. Lilja-Fischer, Jesper G. Eriksen, Jeanette B. Georgsen, Thao T. Vo, Stine R. Larsen, Jonathan Cheng, Michael Busch-Sørensen, Deepti Aurora-Garg, Torben Steiniche, Jens Overgaard
Acta Oncologica.2020; 59(6): 666. CrossRef
Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment
Lien Lippens, Mieke Van Bockstal, Emiel A. De Jaeghere, Philippe Tummers, Amin Makar, Sofie De Geyter, Koen Van de Vijver, An Hendrix, Katrien Vandecasteele, Hannelore Denys
International Journal of Cancer.2020; 147(2): 554. CrossRef
Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
Victor C. Kok
Frontiers in Oncology.2020;[Epub] CrossRef
The different role of PD-L1 in head and neck squamous cell carcinomas: A meta-analysis
Hui Tang, Xiang Zhou, Yu Ye, Yi Zhou, Chengyu Wu, Yan Xu
Pathology - Research and Practice.2020; 216(1): 152768. CrossRef
Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis
Jing He, Xiao-Fang Chen, Ming-Gao Xu, Jing Zhao
Archives of Oral Biology.2020; 114: 104717. CrossRef
The role of transforming growth factor‐beta in immune suppression and chronic inflammation of squamous cell carcinomas
Alexander A. Strait, Xiao‐Jing Wang
Molecular Carcinogenesis.2020; 59(7): 745. CrossRef
The roles of programmed death ligand 1 in virus-associated cancers
Morvarid Golrokh Mofrad, Donya Taghizadeh Maleki, Ebrahim Faghihloo
Infection, Genetics and Evolution.2020; 84: 104368. CrossRef
Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma
Yong-Xin Cui, Xian-Shuang Su
Open Medicine.2020; 15(1): 292. CrossRef
The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma
Dominik Gurin, Marek Slavik, Marketa Hermanova, Iveta Selingerova, Tomas Kazda, Michal Hendrych, Tetiana Shatokhina, Marcela Vesela
Journal of Oral Pathology & Medicine.2020; 49(9): 886. CrossRef
PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma
Nora Wuerdemann, Sibel E. Gültekin, Katharina Pütz, Claus Wittekindt, Christian U. Huebbers, Shachi J. Sharma, Hans Eckel, Anna B. Schubotz, Stefan Gattenlöhner, Reinhard Büttner, Ernst-Jan Speel, Jens P. Klussmann, Steffen Wagner, Alexander Quaas
International Journal of Molecular Sciences.2020; 21(15): 5228. CrossRef
Evaluation of p16 in Epithelial Ovarian Cancer for a 10-Year Study in Northeast China: Significance of HPV in Correlation with PD-L1 Expression

Xinxin Yang, Qi You, Guodong Yao, Jingshu Geng, Rong Ma, Hongxue Meng
Cancer Management and Research.2020; Volume 12: 6747. CrossRef
Prevalence of high-risk human papillomavirus and its genotype distribution in head and neck squamous cell carcinomas
Yuil Kim, Young-Hoon Joo, Min-Sik Kim, Youn Soo Lee
Journal of Pathology and Translational Medicine.2020; 54(5): 411. CrossRef
The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
Xin-wei Qiao, Jian Jiang, Xin Pang, Mei-chang Huang, Ya-jie Tang, Xin-hua Liang, Ya-ling Tang
Frontiers in Immunology.2020;[Epub] CrossRef
Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma
Barbara Seliger, Chiara Massa, Bo Yang, Daniel Bethmann, Matthias Kappler, Alexander Walter Eckert, Claudia Wickenhauser
International Journal of Molecular Sciences.2020; 21(19): 7032. CrossRef
PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
D. Evrard, M. Hourseau, A. Couvelard, V. Paradis, H. Gauthier, E. Raymond, C. Halimi, B. Barry, S. Faivre
OncoImmunology.2020;[Epub] CrossRef
Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients
Atsumu Kouketsu, Ikuro Sato, Mariko Oikawa, Yoshinaka Shimizu, Hiroki Saito, Tetsu Takahashi, Hiroyuki Kumamoto
Journal of Cranio-Maxillofacial Surgery.2019; 47(1): 33. CrossRef
The value of immunotherapy in head and neck cancer
Paolo Manca, Luis E. Raez, Matthew Salzberg, Jorge Sanchez, Brian Hunis, Christian Rolfo
Expert Opinion on Biological Therapy.2019; 19(1): 35. CrossRef
Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route
Iacopo Panarese, Gabriella Aquino, Andrea Ronchi, Francesco Longo, Marco Montella, Immacolata Cozzolino, Giuseppe Roccuzzo, Giuseppe Colella, Michele Caraglia, Renato Franco
Expert Review of Anticancer Therapy.2019; 19(2): 105. CrossRef
The Double-Edged Sword—How Human Papillomaviruses Interact With Immunity in Head and Neck Cancer
Hao-fan Wang, Sha-sha Wang, Ya-Jie Tang, Yu Chen, Min Zheng, Ya-ling Tang, Xin-hua Liang
Frontiers in Immunology.2019;[Epub] CrossRef
The protective role of carnosic acid in ischemic/reperfusion injury through regulation of autophagy under T2DM
Min Hu, Tianyu Li, Zixiang Bo, Feixiang Xiang
Experimental Biology and Medicine.2019; 244(7): 602. CrossRef
Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva
Fabinshy Thangarajah, Bernd Morgenstern, Caroline Pahmeyer, Lars Mortimer Schiffmann, Julian Puppe, Peter Mallmann, Stefanie Hamacher, Reinhard Buettner, Christina Alidousty, Barbara Holz, Andreas H. Scheel, Anne Maria Schultheis
Journal of Cancer Research and Clinical Oncology.2019; 145(6): 1651. CrossRef
The emergence of long-term survivors in recurrent and metastatic squamous cell head and neck cancer
Florian Castet, Jesús Brenes, Miren Taberna, Ricard Mesía
Current Opinion in Oncology.2019; 31(3): 160. CrossRef
PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas
Giuseppe Riva, Giancarlo Pecorari, Matteo Biolatti, Sara Pautasso, Irene Lo Cigno, Massimiliano Garzaro, Valentina Dell’Oste, Santo Landolfo
Molecular Biology Reports.2019; 46(3): 3333. CrossRef
PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma
Priyadharsini Nagarajan, Christian El-Hadad, Stephen K. Gruschkus, Jing Ning, Courtney W. Hudgens, Oded Sagiv, Neil Gross, Michael T. Tetzlaff, Bita Esmaeli
Investigative Opthalmology & Visual Science.2019; 60(6): 2388. CrossRef
PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma
Yui Hirata-Nozaki, Takayuki Ohkuri, Kenzo Ohara, Takumi Kumai, Marino Nagata, Shohei Harabuchi, Akemi Kosaka, Toshihiro Nagato, Kei Ishibashi, Kensuke Oikawa, Naoko Aoki, Mizuho Ohara, Yasuaki Harabuchi, Yuji Uno, Hidehiro Takei, Esteban Celis, Hiroya Kob
Journal of Translational Medicine.2019;[Epub] CrossRef
転移・再発頭頸部がんに対する分子標的薬と免疫チェックポイント阻害薬のエビデンス

Nippon Jibiinkoka Gakkai Kaiho.2019; 122(6): 848. CrossRef
Prognostic Value of Combined Programmed Cell Death 1 Ligand and p16 Expression Predicting Responsiveness to Radiotherapy in Patients with Oropharyngeal Squamous Cell Carcinoma
Minsu Kwon, Dae Hwan Kim, Ki Ju Cho, Youngchul Kim, Jin Pyeong Kim, Bae Kwon Jeong, Jong Sil Lee, Ji-Hyun Seo, Jung Je Park
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2019; 62(12): 712. CrossRef
Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma
Valerie Cristina, Ruth Gabriela Herrera-Gómez, Petr Szturz, Vittoria Espeli, Marco Siano
International Journal of Molecular Sciences.2019; 20(21): 5399. CrossRef
The expression of PD-L1 in salivary gland carcinomas
Domenic Vital, Kristian Ikenberg, Holger Moch, Matthias Rössle, Gerhard F. Huber
Scientific Reports.2019;[Epub] CrossRef
Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis
Yi-Qun Jia, Bo Yang, Li-Ling Wen, Wen-Xin Mu, Zhi Wang, Bin Cheng
Aging.2019; 11(2): 501. CrossRef
Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance
Nabil F. Saba, Zhuo Gerogia Chen, Missak Haigentz, Paolo Bossi, Alessandra Rinaldo, Juan P. Rodrigo, Antti A. Mäkitie, Robert P. Takes, Primoz Strojan, Jan B. Vermorken, Alfio Ferlito
Molecular Cancer Therapeutics.2019; 18(11): 1909. CrossRef
PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma
Juan C. de Vicente, Tania Rodríguez-Santamarta, Juan P. Rodrigo, Verónica Blanco-Lorenzo, Eva Allonca, Juana M. García-Pedrero
Cancer Epidemiology, Biomarkers & Prevention.2019; 28(3): 546. CrossRef
Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma
Theresa Scognamiglio, Yao-Tseng Chen
Head and Neck Pathology.2018; 12(2): 221. CrossRef
The Current State of Biological and Clinical Implications of Human Papillomavirus-Related Oropharyngeal Cancer
Shao Hui Huang, Brian O'Sullivan, John Waldron
Seminars in Radiation Oncology.2018; 28(1): 17. CrossRef
Implications of the tumor immune microenvironment for staging and therapeutics
Janis M Taube, Jérôme Galon, Lynette M Sholl, Scott J Rodig, Tricia R Cottrell, Nicolas A Giraldo, Alexander S Baras, Sanjay S Patel, Robert A Anders, David L Rimm, Ashley Cimino-Mathews
Modern Pathology.2018; 31(2): 214. CrossRef
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments
Benjamin Solomon, Richard J. Young, Danny Rischin
Seminars in Cancer Biology.2018; 52: 228. CrossRef
Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs
Stefano Cavalieri, Licia Rivoltini, Cristiana Bergamini, Laura D. Locati, Lisa Licitra, Paolo Bossi
Cancer Treatment Reviews.2018; 65: 78. CrossRef
Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transition
Mi Jung Kwon, Young-Soo Rho, Eun Sook Nam, Seong Jin Cho, Hye-Rim Park, Soo Kee Min, Jinwon Seo, Ji-Young Choe, Eun Soo Kim, Bumjung Park, Mineui Hong, Kyueng-Whan Min
Human Pathology.2018; 80: 28. CrossRef
The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus–Associated Head and Neck Squamous Cell Carcinoma
Christine Kunkle, Flavia G Rosado
Archives of Pathology & Laboratory Medicine.2018; 142(6): 719. CrossRef
Genomic Landscapes of EBV-Associated Nasopharyngeal Carcinoma vs. HPV-Associated Head and Neck Cancer
Hoi-Lam Ngan, Lan Wang, Kwok-Wai Lo, Vivian Wai Yan Lui
Cancers.2018; 10(7): 210. CrossRef
PD‐1 and PD‐L1 expression in HNSCC primary cancer and related lymph node metastasis – impact on clinical outcome
Sven Schneider, Lorenz Kadletz, Robert Wiebringhaus, Lukas Kenner, Edgar Selzer, Thorsten Füreder, Orsolya Rajky, Anna S Berghoff, Matthias Preusser, Gregor Heiduschka
Histopathology.2018; 73(4): 573. CrossRef
The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis
Wei-fa Yang, May C.M. Wong, Peter J. Thomson, Kar-Yan Li, Yu-xiong Su
Oral Oncology.2018; 86: 81. CrossRef
Prognostic value of PD -L1 expression in patients with primary solid tumors
Xiao Xiang, Peng-Cheng Yu, Di Long, Xiao-Li Liao, Sen Zhang, Xue-Mei You, Jian-Hong Zhong, Le-Qun Li
Oncotarget.2018; 9(4): 5058. CrossRef
Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy
Tatiana Lepikhova, Piia-Riitta Karhemo, Riku Louhimo, Bhagwan Yadav, Astrid Murumägi, Evgeny Kulesskiy, Mikko Kivento, Harri Sihto, Reidar Grénman, Stina M. Syrjänen, Olli Kallioniemi, Tero Aittokallio, Krister Wennerberg, Heikki Joensuu, Outi Monni
Molecular Cancer Therapeutics.2018; 17(9): 2060. CrossRef
Immune check point inhibitors for head and neck cancer
Naomi Kiyota
Toukeibu Gan.2018; 44(4): 336. CrossRef
Immune check point inhibitors for head and neck cancer and its proper management on utilizing head and neck cancer collaborative program
Naomi Kiyota
Journal of Japanese Society of Oral Oncology.2018; 30(4): 144. CrossRef
Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study
Matthias Troeltzsch, Timothy Woodlock, Alix Pianka, Sven Otto, Markus Troeltzsch, Michael Ehrenfeld, Thomas Knösel
Journal of Oral and Maxillofacial Surgery.2017; 75(5): 969. CrossRef
Actualités sur l’immunothérapie en pathologie des voies aérodigestives supérieures
Sophie Outh-Gauer, Christophe Le Tourneau, Chloé Broudin, Florian Scotte, Hélène Roussel, Stéphane Hans, Marion Mandavit, Eric Tartour, Cécile Badoual
Annales de Pathologie.2017; 37(1): 79. CrossRef
Overview of Sinonasal and Ventral Skull Base Malignancy Management
Peter F. Svider, Michael Setzen, Soly Baredes, James K. Liu, Jean Anderson Eloy
Otolaryngologic Clinics of North America.2017; 50(2): 205. CrossRef
PD-L1 expression and CD8+ infiltration shows heterogeneity in Juvenile Recurrent Respiratory Papillomatosis
Tingyu Liu, Max Greenberg, Carissa Wentland, Brandon Sepe, Sarah Bowe, Gillian Diercks, Tiffany Huynh, Mari Mino-Kenudson, Richard Schlegel, David Kodack, Cyril Benes, Jeffrey Engelman, Christopher Hartnick
International Journal of Pediatric Otorhinolaryngo.2017;[Epub] CrossRef
Programmed cell death ligand 1 as a biomarker in head and neck cancer
Sara I. Pai, William C. Faquin
Cancer Cytopathology.2017; 125(7): 529. CrossRef
Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck
Astrid De Meulenaere, Tijl Vermassen, Sandrine Aspeslagh, Wouter Huvenne, Jo Van Dorpe, Liesbeth Ferdinande, Sylvie Rottey
Oral Oncology.2017; 70: 34. CrossRef
Time to change perspectives on HPV in oropharyngeal cancer. A systematic review of HPV prevalence per oropharyngeal sub-site the last 3 years
Linnea Haeggblom, Torbjörn Ramqvist, Massimo Tommasino, Tina Dalianis, Anders Näsman
Papillomavirus Research.2017; 4: 1. CrossRef
The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
Panagiotis Balermpas, Franz Rödel, Mechthild Krause, Annett Linge, Fabian Lohaus, Michael Baumann, Inge Tinhofer, Volker Budach, Ali Sak, Martin Stuschke, Eleni Gkika, Anca-Ligia Grosu, Amir Abdollahi, Jürgen Debus, Stefan Stangl, Ute Ganswindt, Claus Bel
International Journal of Cancer.2017; 141(3): 594. CrossRef
Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis
Ji Li, Ping Wang, Youliang Xu, Jung Weon Lee
PLOS ONE.2017; 12(6): e0179536. CrossRef
Association between PD-L1 and HPV status and the prognostic value for HPV treatment in premalignant cervical lesion patients
Feng Yang-Chun, Cheng Zhen-Zhen, Huang Yan-Chun, Ma Xiu-Min
Medicine.2017; 96(25): e7270. CrossRef
Expressions of programmed death (PD)‐1 and PD‐1 ligand (PD‐L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status
Wen Yang, Yan‐Ping Lu, Yi‐Zhou Yang, Jia‐Rui Kang, Yi‐Duo Jin, Hong‐Wei Wang
Journal of Obstetrics and Gynaecology Research.2017; 43(10): 1602. CrossRef
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
Chiun Hsu, Se-Hoon Lee, Samuel Ejadi, Caroline Even, Roger B. Cohen, Christophe Le Tourneau, Janice M. Mehnert, Alain Algazi, Emilie M.J. van Brummelen, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Aaron R. Hansen
Journal of Clinical Oncology.2017; 35(36): 4050. CrossRef
Human papillomavirus-related oropharyngeal cancer
M. Taberna, M. Mena, M.A. Pavón, L. Alemany, M.L. Gillison, R. Mesía
Annals of Oncology.2017; 28(10): 2386. CrossRef
Circulating tumour cell PD-L1 test for head and neck cancers
Arutha Kulasinghe, Liz Kenny, Chamindie Punyadeera
Oral Oncology.2017; 75: 6. CrossRef
Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer
Astrid De Meulenaere, Tijl Vermassen, Sandrine Aspeslagh, Philippe Deron, Fréderic Duprez, Debby Laukens, Jo Van Dorpe, Liesbeth Ferdinande, Sylvie Rottey
Oncotarget.2017; 8(46): 80443. CrossRef
Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
Axel Lechner, Hans Schlößer, Sacha I. Rothschild, Martin Thelen, Sabrina Reuter, Peter Zentis, Alexander Shimabukuro-Vornhagen, Sebastian Theurich, Kerstin Wennhold, Maria Garcia-Marquez, Lars Tharun, Alexander Quaas, Astrid Schauss, Jörg Isensee, Tim Huc
Oncotarget.2017; 8(27): 44418. CrossRef
Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology
Thomas Hecking, Thore Thiesler, Cynthia Schiller, Jean-Marc Lunkenheimer, Tiyasha H. Ayub, Andrea Rohr, Mateja Condic, Mignon-Denise Keyver-Paik, Rolf Fimmers, Jutta Kirfel, Walther Kuhn, Glen Kristiansen, Kirsten Kübler
Oncotarget.2017; 8(54): 92890. CrossRef
Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data
Gustavo Dix Junqueira Pinto, Luciano de Souza Viana, Cristovam Scapulatempo Neto, Sérgio Vicente Serrano
Journal of Immunology Research.2016; 2016: 1. CrossRef
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
Marlon C. Rebelatto, Anita Midha, Amita Mistry, Constantine Sabalos, Nicole Schechter, Xia Li, Xiaoping Jin, Keith E. Steele, Paul B. Robbins, John A. Blake-Haskins, Jill Walker
Diagnostic Pathology.2016;[Epub] CrossRef
Current clinical immunotherapeutic approaches for head and neck cancer
Carolina Soto Chervin, Bruce Brockstein
F1000Research.2016; 5: 803. CrossRef
PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials
Angela M Hong, Ricardo E Vilain, Sarah Romanes, Jean Yang, Elizabeth Smith, Deanna Jones, Richard A Scolyer, C Soon Lee, Mei Zhang, Barbara Rose
Oncotarget.2016; 7(47): 77010. CrossRef

17,346 View
346 Download
111 Web of Science
104 Crossref

Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer: Ji Yun Lee, Sung Hee Lim, Min-Young Lee, Haesu Kim, Moonjin Kim, Sungmin Kim, Hyun Ae Jung, Insuk Sohn, Won Ho Gil, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park; Cancer Res Treat. 2015;47(4):765-773. Published online January 13, 2015; DOI: https://doi.org/10.4143/crt.2014.168

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to evaluate the role of regular postoperative surveillance to improve the prognosis of patients with breast cancer after curative surgery. Materials and Methods We retrospectively analyzed the medical records of 4,119 patients who received curative surgery for breast cancer at Samsung Medical Center between January 2000 and September 2008. Patients were divided into two groups (group I, regular postoperative surveillance; group II, control group) according to their post-therapy follow-up status for the first 5 years after surgery. Results Among the 3,770 patients selected for inclusion, groups I and II contained 3,300 (87%) and 470 (13%) patients, respectively. The recurrence rates at 5 years for groups I and II were 10.6% and 16.4%, respectively (hazard ratio, 0.85; 95% confidence interval [CI], 0.67 to 1.09; p=0.197). The 10-year mortality cumulative rates were 8.8% for group I and 25.4% for group II (hazard ratio, 0.28; 95% CI, 0.22 to 0.35; p < 0.001). In multivariate analysis for recurrence-free survival (RFS), age over 40 years (p < 0.001), histologic grade 1 (p < 0.001), and pathologic stage I (p < 0.001) were associated with longer RFS but not with follow- up status. Multivariate analysis for overall survival (OS) revealed that patients in group I showed significantly improved OS (hazard ratio, 0.29; 95% CI, 0.23 to 0.37; p < 0.001). Additionally, age over 40 years, histologic grade I, and pathologic stage I were independent prognostic factors for OS. Conclusion Regular follow-up for patients with breast cancer after primary surgery resulted in clinically significant improvements in patient OS.

Citations

Citations to this article as recorded by

Follow-up strategy and survival for five common cancers: A meta-analysis
Boris Galjart, Diederik J. Höppener, Joachim G.J.V. Aerts, Christiaan H. Bangma, Cornelis Verhoef, Dirk J. Grünhagen
European Journal of Cancer.2022; 174: 185. CrossRef
Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry
Ji-Yeon Kim, Danbee Kang, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jong Han Yu, Se Kyung Lee, Young-Hyuck Im, Jin Seok Ahn, Eliseo Guallar, Juhee Cho, Yeon Hee Park
Journal of Global Oncology.2019; (5): 1. CrossRef
Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice
Angela Lamarca, Hamish Clouston, Jorge Barriuso, Mairéad G McNamara, Melissa Frizziero, Was Mansoor, Richard A Hubner, Prakash Manoharan, Sarah O’Dwyer, Juan W Valle
Journal of Clinical Medicine.2019; 8(10): 1630. CrossRef
Analysis of patient-detected breast cancer recurrence
Trishul Kapoor, Sean Wrenn, Peter Callas, Ted A. James
Breast Disease.2017; 37(2): 77. CrossRef

12,248 View
90 Download
3 Web of Science
4 Crossref

Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer: Seung Tae Kim, Tae Won Kim, Kyu-pyo Kim, Tae-You Kim, Sae-Won Han, Ji Yun Lee, Sung Hee Lim, Min-Young Lee, Haesu Kim, Young Suk Park; Cancer Res Treat. 2015;47(4):790-795. Published online December 2, 2014; DOI: https://doi.org/10.4143/crt.2014.126

Abstract PDF PubReader ePub

Purpose
Regorafenib, an oral multi-targeted tyrosine kinase inhibitor, is considered the new standard of care in patients with chemotherapy-refractory colorectal cancers (CRCs). However, there are no data on this drug in Korean patients.
Materials and Methods
We evaluated patients who received oral regorafenib 160 mg once daily during the first 3 weeks of each 4-week cycle between August 2013 and September 2013. All patients had previously progressed fluorouracil, irinotecan, and oxaliplatin with or without biologic agents such as cetuximab or bevacizumab.
Results
Thirty-two patients were enrolled (median age, 57 years; male:female ratio, 20:12; Eastern Cooperative Oncology Group performance status [0-1:2], 31:1; colon:rectum, 21:11). The overall response rate was 3.1% and the disease control rate was 50.0% (95% confidence interval [CI]) with one partial response and 15 patients with stable disease. The median progression-free survival was 4.2 months (95% CI, 3.1 to 5.2 months) and the median overall survival has not yet been reached. The most common adverse events of grade two or higher related to regorafenib were hand-foot skin reaction (25%), mucositis (19%), abdominal pain (9%), and liver function test (LFT) abnormalities (9%). Grade 3 or 4 toxicities included LFT abnormalities (9%), abdominal pain (9%), rash (6%), anemia (3%), leukopenia (3%), neutropenic fever (3%), and fatigue (3%). There was no treatment-related death.
Conclusion
Regorafenib appears to have promising activity and tolerable toxicity profiles in Korean patients with refractory CRC, consistent with the CORRECT trial findings.

Citations

Citations to this article as recorded by

Salvage Treatment Option for Metastatic Colorectal Cancer:Regorafenib
Havva YESİL CİNKİR
SDÜ Tıp Fakültesi Dergisi.2020; 27(4): 471. CrossRef
Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review
Maria Røed Skårderud, Anne Polk, Kirsten Kjeldgaard Vistisen, Finn Ole Larsen, Dorte Lisbet Nielsen
Cancer Treatment Reviews.2018; 62: 61. CrossRef
The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong
Ka-On Lam, Kin-Chung Lee, Joanne Chiu, Victor Ho-Fun Lee, Roland Leung, T S Choy, Thomas Yau
Postgraduate Medical Journal.2017; 93(1101): 395. CrossRef
Pseudocirrhosis caused by regorafenib in an advanced rectal cancer patient with multiple liver metastases
Kensuke Kumamoto, Shungo Endo, Noriyuki Isohata, Azuma Nirei, Daiki Nemoto, Kenichi Utano, Takuro Saito, Kazutomo Togashi
Molecular and Clinical Oncology.2017; 6(1): 63. CrossRef
Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib
Bin Zhao, Hong Zhao
Oncotarget.2017; 8(55): 93813. CrossRef
Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice
Fabien Calcagno, Sabrina Lenoble, Zaher Lakkis, Thierry Nguyen, Samuel Limat, Christophe Borg, Marine Jary, Stefano Kim, Virginie Nerich
Clinical Medicine Insights: Oncology.2016;[Epub] CrossRef

12,637 View
148 Download
13 Web of Science
6 Crossref

Case Report

Tumor Lysis Syndrome in a Solid Tumor: A Case Report of a Patient with Invasive Thymoma: Ji Yun Lee, Sung Hee Lim, Ji Young Lee, Ji Hoon Kim, Ki Hong Choi, Keunchil Park, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn; Cancer Res Treat. 2013;45(4):343-348. Published online December 31, 2013; DOI: https://doi.org/10.4143/crt.2013.45.4.343

Abstract PDF PubReader ePub

Tumor lysis syndrome (TLS) has rarely been observed in solid tumors. We report on a case of a patient with advanced invasive thymoma who developed tumor lysis syndrome after chemotherapy. The potential complications of TLS should be considered in treatment of extensive thymoma.

Citations

Citations to this article as recorded by

Spontaneous tumour lysis syndrome as a rare presentation of thymoma with peripheral blood lymphocytosis
Larry E Nyanti, Andy Sing Ong Tang, Adam Malik b Ismail, Lee Ping Chew, Tze Shin Leong
Proceedings of Singapore Healthcare.2022;[Epub] CrossRef
Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases
Riyadh M Alqurashi , Husam H Tamim, Ziyad D Alsubhi, Alyazid A Alzahrani, Emad Tashkandi
Cureus.2022;[Epub] CrossRef
Spontaneous tumour lysis syndrome in cervical cancer
Yu Kyung Kim, Ji Yeon Ham, Won-Kil Lee, Kyung Eun Song
Journal of Obstetrics and Gynaecology.2017; 37(5): 679. CrossRef
Ifosfamide/mesna/paclitaxel

Reactions Weekly.2015; 1547(1): 151. CrossRef
Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature
Aibek E. Mirrakhimov, Alaa M. Ali, Maliha Khan, Aram Barbaryan
Rare Tumors.2014; 6(2): 68. CrossRef

11,305 View
58 Download
4 Web of Science
5 Crossref

First
Prev
Page of 1
Next
Last

Search